Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
C3 GlomerulopathyMembranoproliferative GlomerulonephritisComplement AbnormalityDense Deposit DiseaseC3 Glomerulonephritis
Interventions
DRUG

Aliskiren

Patients will be randomized to start treatment with aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight. After 6 months switch to enalapril 2.5-20 mg daily and continue with that 2.5 years.

DRUG

Enalapril

Patients will be randomized to start with enalapril 2.5-20 mg daily depending on weight. After 6 months switch to aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight and continue with this treatment for 2.5 years.

Trial Locations (4)

22184

RECRUITING

Region Skåne Skåne Universitetssjukhus, Lund

Unknown

NOT_YET_RECRUITING

Sahlgrenska Hospital, Gothenburg

NOT_YET_RECRUITING

Karolinska Hospital, Stockholm

NOT_YET_RECRUITING

Akademiska sjukhuset, Uppsala

All Listed Sponsors
lead

Region Skane

OTHER